4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$6.60 USD
-0.50 (-7.04%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $6.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FDMT 6.60 -0.50(-7.04%)
Will FDMT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FDMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FDMT
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
FDMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
Other News for FDMT
Is FDMT preparing to trend lower? Fell Below 20 Day Moving Average shows up after crashing 7.04%
H.C. Wainwright Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)
Crossed Above 20 Day Moving Average appears for FDMT after 6.61% move
FDMT forms 20 Day Moving Average Resistance on September 17
FDMT forms 1,2,3 Pullback Bullish on September 16